Osmotic Laxative Drug Class List

Drugs in Drug Class: Osmotic Laxative

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Riley Consumer	ZEGERID OTC	omeprazole; sodium bicarbonate	CAPSULE;ORAL	022281-001	Dec 1, 2009		OTC	Yes	Yes
Aurobindo Pharma Usa	TRILYTE	polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride	FOR SOLUTION;ORAL	076491-001	Feb 5, 2004	AA	RX	No	No
Hospira	TPN ELECTROLYTES IN PLASTIC CONTAINER	calcium chloride; magnesium chloride; potassium chloride; sodium acetate; sodium chloride	INJECTABLE;INJECTION	018895-001	Jul 20, 1984		RX	Yes	Yes
Baxter Hlthcare	TIS-U-SOL	magnesium sulfate; potassium chloride; potassium phosphate, monobasic; sodium chloride; sodium phosphate	SOLUTION;IRRIGATION	018508-001	Feb 19, 1982	AT	RX	No	No

Osmotic Laxative Market Dynamics and Patent Landscape (Key Patents, Exclusivity Timelines, and Generic Entry Risks)

Last updated: July 27, 2026

The osmotic laxative class is dominated by off-patent small molecules (notably polyethylene glycol, lactulose, magnesium salts, and sodium picosulfate formulations), so the near-term IP landscape is driven less by new active ingredients and more by formulation, delivery, and method-of-use patents plus label exclusivity and Orange Book listing coverage. Patent protection is typically concentrated in fixed-dose prescription products (including bowel-prep regimens), brand-specific combination products, and manufacturing/process claims. Generic entry risk is highest once Orange Book-listed patents expire or are cleared through Paragraph IV litigation or settlement.

What patents protect osmotic laxatives (polyethylene glycol, lactulose, magnesium, sodium picosulfate)?

Short answer: Most osmotic laxatives rely on older, broadly protected actives with limited remaining active-ingredient patent coverage. Current patent estates usually cover formulation details (molecular weight distribution, osmolality targets, electrolyte content), product-specific dosing regimens (bowel prep vs chronic constipation), and manufacturing/process steps, plus discrete method-of-use claims aligned to prescriber workflows and labeling.

Which active ingredients define the osmotic laxative patent estates?

Common osmotic laxatives and how patents typically appear:

1. Polyethylene glycol (PEG 3350/PEG electrolyte solutions)
   • Patent themes: composition of electrolytes with PEG, dose regimen for bowel preparation, manufacturing purification specs, and sometimes device/sachet formats.
2. Lactulose
   • Patent themes: process/production claims (less common in current litigation), plus specific formulations and controlled-release variants (rare versus off-patent core).
3. Magnesium salts (magnesium hydroxide, magnesium citrate, magnesium sulfate)
   • Patent themes: branded formulations, taste/matrix modifications, and combination with other actives (less frequent in active litigation).
4. Sodium picosulfate with magnesium oxide or citrate
   • Patent themes: fixed combination formulations, tablet/sachet stability and release kinetics, and bowel prep regimens.

How many patents cover “osmotic laxative” products in practice?

A typical pattern in this class:

• A limited number of Orange Book-listed patents per branded product (often a mix of composition and method-of-use).
• A larger set of non-Orange Book patent families (device, packaging, process, and formulation improvements) that do not control FDA generic approval but can matter in product design around litigation.

Because osmotic laxatives are widely genericized, the most litigation-relevant patents are the ones listed in the Orange Book for the reference listed drug (RLD) and those tied to the exact dosage form and regimen.

When do osmotic laxative patents lose exclusivity (drug-by-drug expiration and exclusivity drivers)?

Short answer: Exclusivity timing in osmotic laxatives is usually defined by the last surviving Orange Book patent on each branded RLD, with generic entry often occurring shortly after expiration or after resolution of Paragraph IV challenges. For many actives, active-ingredient coverage is already expired; what remains tends to be product-specific patents.

What timing levers matter for osmotic laxatives?

1. Orange Book patent expiration
   • Determines when ANDA exclusivity barriers tied to listed patents can be removed.
2. Regulatory exclusivities
   • 3-year new chemical entity exclusivity is unlikely given older actives.
   • 5-year new drug exclusivity and pediatric exclusivity may appear for reformulations or new indications, but this class often relies on label extensions rather than novel actives.
3. Bowel prep regimen lifecycles
   • Bowel preparation products are frequently renewed through formulation and dosing-regimen updates that can extend business leverage even when the active ingredients are long genericized.

Typical expiration pattern by product category

• Chronic constipation brands: fewer late-life formulation patents, faster generic normalization.
• Bowel prep regimens: more likely to have late-life formulation/device/procedure patents and larger settlement activity.
• Combination products: more frequent combination-protected compositions with clearer “work-around” design constraints.

What is the Orange Book status of osmotic laxative products (and how does it shape generic entry)?

Short answer: For most widely used osmotic laxatives, the Orange Book landscape is either fully expired (enabling multiple generics) or includes a small number of late-life listed patents on the brand’s exact dosage form. The Orange Book status is the decisive first filter for ANDA design-around risk.

Orange Book status mechanics that matter for ANDAs

1. Which listed patents cover the exact dosage form
   • Generics must address patents tied to that dosage strength and drug product.
2. Patent expiration vs pediatric exclusivity and stays
   • Even after expiration, the presence of a court-imposed stay (from Paragraph IV litigation) can delay effective approval.
3. “Carve-out” risk
   • Formulation changes can sometimes avoid composition patents but may not avoid method-of-use patents that track labeling.

Which companies are challenging osmotic laxative patents (Paragraph IV and ANDA litigation patterns)?

Short answer: Challenge activity is highest in bowel-prep and branded reformulation segments where at least one Orange Book patent remains. In these segments, multiple generic manufacturers typically file ANDAs with different Paragraph IV strategies, driving multi-defendant litigation and settlement-driven launch timing.

How Paragraph IV filings usually cluster in this class

• Single RLD, multiple challengers
  • Common when a brand still has a handful of listed patents.
• Settlement drives “date-based” launches
  • Even when patents are contested, market entry is often synchronized to a settlement or to a final court date.

Litigation outcomes that most affect business decisions

• Early dismissal or non-infringement rulings
  • Can accelerate generic approval.
• Injunction scope
  • Can limit launch to certain strengths, package sizes, or dosing regimens.
• Remaining patent families
  • Post-settlement, companies still face follow-on patents if the brand has multiple families listed or asserted in later waves.

What formulations are protected by osmotic laxative patents (PEG-electrolyte, lactulose blends, magnesium combinations)?

Short answer: Formulation protection is typically concentrated in:

• PEG plus electrolytes at defined concentrations and ratios,
• sodium phosphate or citrate-based compositions combined with osmotic agents,
• stability-controlled blend specs and release behavior,
• controlled dose regimens aligned to labeled directions.

Formulation patent themes that affect design-around

1. Electrolyte composition and ratios
   • Changing cation/anions or their concentrations can avoid composition claims but may shift osmolality profile and trigger labeling mismatch.
2. PEG molecular weight distribution
   • Patents can claim specific molecular weight windows or functional parameters.
3. Fill method and reconstitution characteristics
   • Some claims target processing that impacts patient usability or absorption.

Dosage form and packaging patents

These can be commercially relevant:

• sachet vs bottle vs unit-dose formats,
• reconstitution steps,
• device-integrated dosing (less common but appears in bowel prep).

What method-of-use patents exist for osmotic laxatives (chronic constipation vs bowel preparation)?

Short answer: Method-of-use patents are a frequent late-life lever in this class, especially where labeled directions specify dosing schedules and patient groups. Generic entrants may be forced into labeling carve-outs to avoid infringement, which can reduce commercial viability even if approval is granted.

Label-dependent infringement risk

• Bowel prep regimens
  • Method-of-use claims often track multi-day or day-of preparation timing and associated dietary restrictions.
• Chronic constipation
  • Method claims can track titration schedules or specific patient populations.

How does osmotic laxative patent strength compare across PEG vs lactulose vs magnesium vs sodium picosulfate?

Short answer: Patent strength is typically strongest where branded products remain tied to late-life reformulations and bowel-prep regimens. PEG-based bowel-prep and branded PEG electrolyte formulations often carry the most business-relevant patent estates. Lactulose and magnesium actives generally have weaker late-life brand value in the US market due to broad generic coverage. Sodium picosulfate combinations vary by brand and region but tend to face faster generic saturation in mature segments.

Comparative commercial leverage drivers

• Clinical differentiation
  • Brands with differentiated instructions can map to method-of-use claims.
• Regimen complexity
  • More complex regimens correlate with more protectable composition and dosing-details.
• Switching friction
  • If pharmacy benefit design or hospital protocols favor a brand-specific regimen, patent leverage translates into revenue protection longer than exclusivity would suggest.

How do FDA pathway choices affect generic entry risk for osmotic laxatives?

Short answer: Most generics use ANDAs for established osmotic laxative products. Where brand products are tied to complex formulations or specific instructions, the generic’s ability to match product and labeling becomes the entry constraint, and design-around of method-of-use claims can become commercially meaningful.

ANDA-specific risk points

• Paragraph IV notice alignment
  • Filing strategy depends on which patents are Orange Book-listed and enforceable.
• Labeling carve-outs
  • If the generic chooses a narrow label to avoid infringement, volume can drop even if approval occurs.

What generic entry risks exist for osmotic laxative drugs (launch timing, design-around, and settlement barriers)?

Short answer: Generic entry risk in osmotic laxatives is driven by three practical barriers:

1. remaining Orange Book-listed patents on the RLD dosage form,
2. court stays or ongoing litigation that blocks “effective approval,”
3. label design constraints required to avoid method-of-use or regimen-specific infringement.

Generic launch scenarios that recur in the class

• Scenario A: Orange Book expiration without litigation
  • Generic launches quickly once patents expire.
• Scenario B: Paragraph IV with settlement
  • Generic launches on a date agreed in settlement, often before full patent expiration.
• Scenario C: Litigation continues
  • Approval is delayed by stays or injunctions; partial launch occurs only if carve-outs are legally cleared.

Revenue exposure: where osmotic laxative spending is most sensitive to patent expiration

Short answer: Spending exposure concentrates in:

• bowel-prep products used in outpatient and inpatient endoscopy workflows,
• branded constipation products that retain payer coverage through differentiation (pack size, regimen instructions, and formulary placement).

Business impact channels

• Payer switching behavior
  • After approval of authorized/at-risk generics, payer substitution is usually fast once labeling is acceptable.
• Channel contracting
  • Contracts with hospitals/ASC settings can delay generic uptake even after exclusivity ends.
• Multiple-source dynamics
  • Once two or more multisource generics exist, price compression typically accelerates.

Key Takeaways

• Osmotic laxatives are largely off-active-ingredient patent, so the enforceable estate typically centers on formulation, packaging, and method-of-use patents listed in the Orange Book for specific branded RLD dosage forms.
• Patent protection is most commercially material in bowel-prep regimens and branded PEG-electrolyte products where method-of-use and regimen-specific directions can require labeling carve-outs.
• Generic entry is usually gated by Orange Book-listed patents plus Paragraph IV-driven litigation stays and settlement-triggered launch dates.
• Competitive risk is highest for brands with active Orange Book listings and ongoing Paragraph IV challenges; label alignment is often the make-or-break factor for generics even when formulation design-around is feasible.

FAQs

1. Which osmotic laxatives have the most remaining Orange Book-listed patents in the US?
2. Do method-of-use patents on osmotic laxatives force generic labeling carve-outs or product redesign?
3. How do Paragraph IV settlements in bowel-prep products typically set generic launch dates?
4. What formulation parameters (PEG molecular weight, electrolyte ratios) are most commonly patented in osmotic laxatives?
5. How quickly do pharmacy formularies shift to multisource generics after patent expiration for osmotic laxatives?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. FDA. ANDA regulations and paragraph IV litigation framework (Hatch-Waxman).